Last $22.49 USD
Change Today -0.34 / -1.49%
Volume 815.0K
SRPT On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (SRPT) Snapshot

Open
$23.10
Previous Close
$22.83
Day High
$23.20
Day Low
$22.28
52 Week High
10/24/13 - $44.29
52 Week Low
11/13/13 - $12.12
Market Cap
920.4M
Average Volume 10 Days
1.8M
EPS TTM
$-3.07
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (SRPT)

sarepta therapeutics inc (SRPT) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (SRPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (SRPT) Key Developments

Sarepta Therapeutics, Inc. Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy

Sarepta Therapeutics, Inc. announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company's drug candidates for the treatment of Ebola and Marburg virus, respectively. The study results are to be published in the November issue of the American Society for Microbiology's journal, Antimicrobial Agents and Chemotherapy and are available online at dx.doi.org/10.1128/AAC.03442-14. AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers (PMOs AVI-7537 and AVI-7539), which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, (AVI-7287 and AVI-7288), which target the viral proteins VP24 and NP, respectively. These drug candidates use Sarepta's advanced and proprietary PMOplus(R) chemistry, which is also the basis of the company's clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288. The two Phase I clinical studies were randomized, double-blind, placebo-controlled trials designed to characterize the safety, tolerability and pharmacokinetics of single doses of intravenous formulations of AVI-6002 or AVI-6003 in healthy adult volunteers. In each study, 30 subjects were enrolled in six cohorts receiving up to 9 mg/kg of the combination drug candidates (4 active:1 placebo per cohort) for a total of 60 subjects. Results showed the compounds to be well-tolerated with no dose limiting level demonstrated. No clinically significant or dose-dependent effects were observed at any of the safety endpoints evaluated. The safety and pharmacokinetics of the four PMOplus(R) compounds comprising the two combination therapies were similar, regardless of the target RNA sequence.

Sarepta Therapeutics, Inc. Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

Sarepta Therapeutics, Inc. announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company's lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between the company and the NIH's National Institute of Allergy and Infectious Diseases. AVI-7100 uses Sarepta's advanced and proprietary PMOplus(TM) chemistry, which is also the basis of the company's clinical-stage Ebola and Marburg drug candidates. The Phase I clinical study is a randomized, double-blind, placebo-controlled trial designed to characterize the safety, tolerability and pharmacokinetics of single and multiple doses of an intravenous formulation of AVI-7100 in healthy adult volunteers. In the completed single ascending dose portion, 40 subjects were enrolled in five cohorts (6 active: 2 placebo) up to the high dose tested of 8 mg/kg AVI-7100. Results showed that AVI-7100 was well-tolerated with no reported serious or clinically significant adverse events. The pharmacokinetic analysis of AVI-7100 reveals a highly similar dose-dependent profile to that of Sarepta's Ebola and Marburg PMOplus drug candidates. An independent Data and Safety Monitoring Board reviewed safety results from the study and recommended the study continue as planned to the multiple dose portion of the study. AVI-7100 utilizes a novel mechanism of action to target a well-conserved region of the influenza A virus, affording it the potential to act as a broad-spectrum treatment for multiple influenza strains, including Tamiflu-resistant flu strains. Seasonal influenza (H3N2) and 2009 H1N1 are both caused by the influenza A virus. Preclinical studies funded by the U.S. Department of Defense demonstrated that AVI-7100 improved clinical symptoms and reduced viral titers in animal models infected with pandemic H1N1 or H3N2 viruses, and had statistically significant activity as compared to saline and Tamiflu controls.

Sarepta Therapeutics, Inc. Presents at Leerink Rare Disease Roundtable, Oct-01-2014 08:00 AM

Sarepta Therapeutics, Inc. Presents at Leerink Rare Disease Roundtable, Oct-01-2014 08:00 AM. Venue: Le Parker Meridian Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $22.49 USD -0.34

SRPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,236 GBp +66.00
Baxter International Inc $68.65 USD +0.71
Gilead Sciences Inc $106.67 USD +4.46
Hemispherx Biopharma Inc $0.32 USD -0.013
SciClone Pharmaceuticals Inc $7.88 USD +0.30
View Industry Companies
 

Industry Analysis

SRPT

Industry Average

Valuation SRPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.3x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.